Selumetinib
Koselugo · MEK inhibitor
Creatinine rise in neurofibromatosis.
Vumon · VM-26
Podophyllotoxin (topo II) · approved 1992 · 5 citations
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
A highly protein-bound podophyllotoxin whose renal relevance is pharmacokinetic — low renal clearance and exposure, not direct nephron injury.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
Minimal direct nephrotoxicity. Teniposide is highly protein-bound with low renal clearance (only ~5-20% of a dose is recovered in urine versus a larger fraction for etoposide), so the kidney is a minor elimination route and direct renal injury is not a characteristic toxicity. Renal relevance is pharmacokinetic/exposure-related and not quantified as a discrete nephrotoxicity rate.Source: Clark, Semin Oncol 1992
No characteristic renal onset; pharmacokinetic exposure effects are immediate but clinically modest.
Distilled from: “No characteristic renal onset; pharmacokinetic exposure effects are immediate but clinically modest.”
This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
Renal electrolyte derangement — magnesium/potassium/calcium wasting (cisplatin, anti-EGFR antibodies) or retention (FGFR-inhibitor hyperphosphatemia, tumor-lysis hyperkalemia/hyperphosphatemia).
Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.
Teniposide (VM-26) is a semisynthetic podophyllotoxin derivative and topoisomerase II poison: it stabilizes the enzyme-DNA cleavable complex, producing double-strand DNA breaks and arrest in late S/early G2 phase. More potent and more highly protein-bound than its analog etoposide, it is used chiefly in childhood acute lymphoblastic leukemia (often refractory disease) and has activity in selected CNS and other tumors.
Proximal Tubule
Bulk reabsorption + drug uptake (OCT2, OATs)
4 primary references — trials, cohorts, mechanism, and reviews. Single-patient case reports are listed separately below, graded by strength. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Single-patient and small-series reports, graded by evidentiary strength — A Strong (biopsy-proven plus a series and/or positive rechallenge), B Moderate, and C Limited (a single clinically-diagnosed case). Strongest first. Grades are inferred automatically from each report's abstract and journal — a heuristic ranking aid, not a formal quality appraisal.
Everything below is FAERS — adverse events someone chose to report, about 405 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-11-15.
What reporting says about this profile's documented lesions
Counted by the report's active-substance field, which FAERS fills almost only on reports received from 2013 on, so these figures describe reports since then, not the agent's whole history.
Reported with a death outcome
88 of 405 reports
Reported with hospitalization
53 of 405 reports
Reports per year
Reports received per year, 2015–2026 · most recent year is partial · 15 of the 405 reports predate 2015 and are not drawn.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Teniposide sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Koselugo · MEK inhibitor
Creatinine rise in neurofibromatosis.
Ganite · Antineoplastic metal salt
Dose-limiting acute tubular necrosis; potentiated by dehydration and concurrent nephrotoxins.
Padcev · Antibody-drug conjugate (Nectin-4/MMAE)
Emerging AKI and electrolyte signals in urothelial cancer.
Darzalex · Anti-CD38 antibody
Tumor lysis; usable in renal impairment.
Sarclisa · Anti-CD38 antibody
Tumor lysis in myeloma.
Sandostatin · Somatostatin analog
Kidney-neutral/possibly renoprotective; renally cleared, caution in severe CKD/dialysis.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.